A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK117 as Monotherapy or in Combination With AK104

NCT04349969 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

38

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms Malignant

Interventions

DRUG: AK117
DRUG: AK117+AK104

Sponsor

Akesobio Australia Pty Ltd